Defining Value With a Changing Biosimilar Landscape

Atheer Kaddis, PharmD, and Sonia T. Oskouei, PharmD, BCMAS, DPLA, provide an overview of biosimilars and the preparation for future launches on the horizon.

Drs Kaddis and Oskouei define interchangeable biosimilars, their FDA requirements, and switching studies.

Mariam Alboustani, PharmD, discusses the one published example of a switching study and the implications of interchangeability for pharmacists, as well as payers.

Dr Sonia T. Oskouei focuses on automatic substitution in both the pharmacy setting and in patients’ health plans.

Drs Atheer Kaddis and Mariam Alboustani delve into biosimilar conversion programs, including switching policies for interchangeability.

Drs Oskouei and Alboustani discuss implications of multiple biosimilars for adalimumab and how indications are extrapolated for a biosimilar.

Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products.

Drs Kaddis and Alboustani conclude with their thoughts on contracting considerations for branded Humira in 2023, as well as what impact an interchangeable biosimilar could have in the future.

Sonia T. Oskouei, PharmD, BCMAS, DPLA, navigates the impact of the VOLTAIRE-X study, the only published switching study for adalimumab, on biosimilar uptake.

Sonia Oskouei explores the managed care landscape and opportunities for increasing biosimilar uptake to improve patient care.

In her final thoughts, Dr Oskouei discusses how patient care may be improved by increased access to biosimilars.